# OnCo record nct02263508 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02263508/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02263508", "NCT02263508" ;
  schema:name "Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma"@en ;
  schema:description "A phase 3 trial of Talimogene laherparepvec and Pembrolizumab in Melanoma, run by Amgen, recorded as terminated on the registry."@en ;
  schema:url <https://onco.cc/trials/nct02263508/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02263508> ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:drugs <https://onco.cc/drugs/talimogene-laherparepvec/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/amgen/> .